{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:23:27Z","timestamp":1773102207246,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00417-019-04287-1","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T21:23:39Z","timestamp":1552166619000},"page":"967-974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis"],"prefix":"10.1007","volume":"257","author":[{"given":"Fang-Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Sang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fung-Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Jong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,9]]},"reference":[{"key":"4287_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ACI.0000000000000299","volume":"16","author":"M Shaker","year":"2016","unstructured":"Shaker M, Salcone E (2016) An update on ocular allergy. Curr Opin Allergy Clin Immunol 16:505\u2013510. \n                    https:\/\/doi.org\/10.1097\/ACI.0000000000000299","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4287_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","volume":"107","author":"S Bonini","year":"2000","unstructured":"Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, Rama P, Magrini L, Juhas T, Bucci MG (2000) Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow-up. Ophthalmology 107:1157\u20131163","journal-title":"Ophthalmology"},{"key":"4287_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","volume":"7","author":"S Bonini","year":"2007","unstructured":"Bonini S, Sacchetti M, Mantelli F, Lambiase A (2007) Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 7:436\u2013441. \n                    https:\/\/doi.org\/10.1097\/ACI.0b013e3282efb726","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4287_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.alit.2016.12.004","volume":"66","author":"E Takamura","year":"2017","unstructured":"Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, Kumagai N, Satake Y, Shoji J, Nakagawa Y, Namba K, Fukagawa K, Fukushima A, Fujishima H, Japanese Society of A (2017) Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 66:220\u2013229. \n                    https:\/\/doi.org\/10.1016\/j.alit.2016.12.004","journal-title":"Allergol Int"},{"key":"4287_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/OPTH.S129552","volume":"12","author":"H Addis","year":"2018","unstructured":"Addis H, Jeng BH (2018) Vernal keratoconjunctivitis. Clin Ophthalmol 12:119\u2013123. \n                    https:\/\/doi.org\/10.2147\/OPTH.S129552","journal-title":"Clin Ophthalmol"},{"key":"4287_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/ACI.0b013e328364ec3a","volume":"13","author":"TP O'Brien","year":"2013","unstructured":"O'Brien TP (2013) Allergic conjunctivitis: an update on diagnosis and management. Curr Opin Allergy Clin Immunol 13:543\u2013549. \n                    https:\/\/doi.org\/10.1097\/ACI.0b013e328364ec3a","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4287_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/bjophthalmol-2011-301376","volume":"97","author":"S Smedt De","year":"2013","unstructured":"De Smedt S, Wildner G, Kestelyn P (2013) Vernal keratoconjunctivitis: an update. Br J Ophthalmol 97:9\u201314. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301376","journal-title":"Br J Ophthalmol"},{"key":"4287_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/112067210101100203","volume":"11","author":"P Verin","year":"2001","unstructured":"Verin P, Allewaert R, Joyaux JC, Piozzi E, Koliopoulos J, Bloch-Michel E, Lodoxamide Study G (2001) Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis. Eur J Ophthalmol 11:120\u2013125","journal-title":"Eur J Ophthalmol"},{"key":"4287_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1089\/jop.2005.21.400","volume":"21","author":"I Corum","year":"2005","unstructured":"Corum I, Yeniad B, Bilgin LK, Ilhan R (2005) Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density. J Ocul Pharmacol Ther 21:400\u2013405. \n                    https:\/\/doi.org\/10.1089\/jop.2005.21.400","journal-title":"J Ocul Pharmacol Ther"},{"key":"4287_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00417-002-0612-6","volume":"241","author":"G D'Angelo","year":"2003","unstructured":"D'Angelo G, Lambiase A, Cortes M, Sgrulletta R, Pasqualetti R, Lamagna A, Bonini S (2003) Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 241:192\u2013195. \n                    https:\/\/doi.org\/10.1007\/s00417-002-0612-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4287_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/bjo.83.2.180","volume":"83","author":"KF Tabbara","year":"1999","unstructured":"Tabbara KF, al-Kharashi SA (1999) Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br J Ophthalmol 83:180\u2013184","journal-title":"Br J Ophthalmol"},{"key":"4287_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s10384-012-0152-5","volume":"56","author":"V Oner","year":"2012","unstructured":"Oner V, Turkcu FM, Tas M, Alakus MF, Iscan Y (2012) Topical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol 56:312\u2013318. \n                    https:\/\/doi.org\/10.1007\/s10384-012-0152-5","journal-title":"Jpn J Ophthalmol"},{"key":"4287_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/ICO.0b013e31822481c2","volume":"31","author":"JH Tzu","year":"2012","unstructured":"Tzu JH, Utine CA, Stern ME, Akpek EK (2012) Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Cornea 31:649\u2013654. \n                    https:\/\/doi.org\/10.1097\/ICO.0b013e31822481c2","journal-title":"Cornea"},{"key":"4287_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1034\/j.1600-0420.1999.770505.x","volume":"77","author":"JS Saini","year":"1999","unstructured":"Saini JS, Gupta A, Pandey SK, Gupta V, Gupta P (1999) Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. Acta Ophthalmol Scand 77:515\u2013518","journal-title":"Acta Ophthalmol Scand"},{"key":"4287_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0002-9394(14)70271-5","volume":"121","author":"DS Holsclaw","year":"1996","unstructured":"Holsclaw DS, Whitcher JP, Wong IG, Margolis TP (1996) Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Am J Ophthalmol 121:243\u2013249","journal-title":"Am J Ophthalmol"},{"key":"4287_CR16","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0161-6420(91)32069-4","volume":"98","author":"JH Bleik","year":"1991","unstructured":"Bleik JH, Tabbara KF (1991) Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 98:1679\u20131684","journal-title":"Ophthalmology"},{"key":"4287_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/eye.2001.10","volume":"15","author":"V Gupta","year":"2001","unstructured":"Gupta V, Sahu PK (2001) Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye (Lond) 15:39\u201341. \n                    https:\/\/doi.org\/10.1038\/eye.2001.10","journal-title":"Eye (Lond)"},{"key":"4287_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","volume":"96","author":"S Smedt De","year":"2012","unstructured":"De Smedt S, Nkurikiye J, Fonteyne Y, Tuft S, De Bacquer D, Gilbert C, Kestelyn P (2012) Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial. Br J Ophthalmol 96:323\u2013328. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2011-300415","journal-title":"Br J Ophthalmol"},{"key":"4287_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1399-3038.2006.00427.x","volume":"17","author":"L Spadavecchia","year":"2006","unstructured":"Spadavecchia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, Bellizzi M, Rizzo G, Procoli U, Bellizzi G, Armenio L (2006) Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 17:527\u2013532. \n                    https:\/\/doi.org\/10.1111\/j.1399-3038.2006.00427.x","journal-title":"Pediatr Allergy Immunol"},{"key":"4287_CR20","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1097\/ICO.0b013e318172fbb1","volume":"27","author":"F Anzaar","year":"2008","unstructured":"Anzaar F, Gallagher MJ, Bhat P, Arif M, Farooqui S, Foster CS (2008) Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea 27:884\u2013888. \n                    https:\/\/doi.org\/10.1097\/ICO.0b013e318172fbb1","journal-title":"Cornea"},{"key":"4287_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2332\/allergolint.13-OA-0605","volume":"63","author":"M Ueta","year":"2014","unstructured":"Ueta M, Sotozono C, Koga A, Yokoi N, Kinoshita S (2014) Usefulness of a new therapy using rebamipide eyedrops in patients with VKC\/AKC refractory to conventional anti-allergic treatments. Allergol Int 63:75\u201381. \n                    https:\/\/doi.org\/10.2332\/allergolint.13-OA-0605","journal-title":"Allergol Int"},{"key":"4287_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/pai.12360","volume":"26","author":"N Pucci","year":"2015","unstructured":"Pucci N, Caputo R, di Grande L, de Libero C, Mori F, Barni S, di Simone L, Calvani A, Rusconi F, Novembre E (2015) Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: a randomized, comparative, double-blind, crossover study. Pediatr Allergy Immunol 26:256\u2013261. \n                    https:\/\/doi.org\/10.1111\/pai.12360","journal-title":"Pediatr Allergy Immunol"},{"key":"4287_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","volume":"98","author":"A Fukushima","year":"2014","unstructured":"Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N, Shoji J, Takamura E, Nakagawa Y, Namba K, Fujishima H, Miyazaki D (2014) Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol 98:1023\u20131027. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304453","journal-title":"Br J Ophthalmol"},{"key":"4287_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00004397-200343010-00007","volume":"43","author":"A Leonardi","year":"2003","unstructured":"Leonardi A, Secchi AG (2003) Vernal keratoconjunctivitis. Int Ophthalmol Clin 43:41\u201358","journal-title":"Int Ophthalmol Clin"},{"key":"4287_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/01.ico.0000183533.14899.8d","volume":"25","author":"M Tanaka","year":"2006","unstructured":"Tanaka M, Dogru M, Takano Y, Miyake-Kashima M, Asano-Kato N, Fukagawa K, Tsubota K, Fujishima H (2006) Quantitative evaluation of the early changes in ocular surface inflammation following MMC-aided papillary resection in severe allergic patients with corneal complications. Cornea 25:281\u2013285. \n                    https:\/\/doi.org\/10.1097\/01.ico.0000183533.14899.8d","journal-title":"Cornea"},{"key":"4287_CR26","volume-title":"Review of medical physiology (LANGE basic science) 22nd Edition","author":"WF Ganong","year":"2005","unstructured":"Ganong WF (2005) Review of medical physiology (LANGE basic science) 22nd Edition. McGraw-Hill Medical, New York City"},{"key":"4287_CR27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S1567-5769(01)00059-5","volume":"1","author":"S Sakuma","year":"2001","unstructured":"Sakuma S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, Amaya T, Goto T (2001) Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (comparison with steroids). Int Immunopharmacol 1:1219\u20131226","journal-title":"Int Immunopharmacol"},{"key":"4287_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ajo.2013.10.006","volume":"157","author":"AM Al-Amri","year":"2014","unstructured":"Al-Amri AM (2014) Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol 157:280\u2013286. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2013.10.006","journal-title":"Am J Ophthalmol"},{"key":"4287_CR29","first-page":"5","volume":"6","author":"U FDA","year":"2000","unstructured":"FDA U (2000) US FDA advisory committee recommends approval of tacrolimus ointment. Skin Therapy Lett 6:5","journal-title":"Skin Therapy Lett"},{"key":"4287_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","volume":"115","author":"D Miyazaki","year":"2008","unstructured":"Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y (2008) Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 115:988\u2013992 e985. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2007.07.025","journal-title":"Ophthalmology"},{"key":"4287_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1468-3083.2008.02933.x","volume":"23","author":"H Zribi","year":"2009","unstructured":"Zribi H, Descamps V, Hoang-Xuan T, Crickx B, Doan S (2009) Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. J Eur Acad Dermatol Venereol 23:489\u2013490. \n                    https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02933.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4287_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/09546630903493329","volume":"21","author":"JM Mandelin","year":"2010","unstructured":"Mandelin JM, Remitz A, Virtanen HM, Malmberg LP, Haahtela T, Reitamo S (2010) A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4\u00a0years. J Dermatol Treat 21:167\u2013170. \n                    https:\/\/doi.org\/10.3109\/09546630903493329","journal-title":"J Dermatol Treat"},{"key":"4287_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/jop.2008.0125","volume":"25","author":"J Yuan","year":"2009","unstructured":"Yuan J, Zhai JJ, Chen JQ, Ye CT, Zhou SY (2009) Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. J Ocul Pharmacol Ther 25:345\u2013350. \n                    https:\/\/doi.org\/10.1089\/jop.2008.0125","journal-title":"J Ocul Pharmacol Ther"},{"key":"4287_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/02713680802149115","volume":"33","author":"L Attas-Fox","year":"2008","unstructured":"Attas-Fox L, Barkana Y, Iskhakov V, Rayvich S, Gerber Y, Morad Y, Avni I, Zadok D (2008) Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 33:545\u2013549. \n                    https:\/\/doi.org\/10.1080\/02713680802149115","journal-title":"Curr Eye Res"},{"key":"4287_CR35","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R (2008) Transdermal drug delivery. Nat Biotechnol 26:1261\u20131268. \n                    https:\/\/doi.org\/10.1038\/nbt.1504","journal-title":"Nat Biotechnol"},{"key":"4287_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ophtha.2016.11.002","volume":"124","author":"D Miyazaki","year":"2017","unstructured":"Miyazaki D, Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Shoji J, Takamura E, Nakagawa Y, Namba K, Fujishima H (2017) Steroid-sparing effect of 0.1% tacrolimus eye drop for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases. Ophthalmology 124:287\u2013294. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2016.11.002","journal-title":"Ophthalmology"},{"key":"4287_CR37","doi-asserted-by":"publisher","first-page":"NC05","DOI":"10.7860\/JCDR\/2016\/17847.7978","volume":"10","author":"RK Barot","year":"2016","unstructured":"Barot RK, Shitole SC, Bhagat N, Patil D, Sawant P, Patil K (2016) Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases. J Clin Diagn Res 10:NC05\u2013NC09. \n                    https:\/\/doi.org\/10.7860\/JCDR\/2016\/17847.7978","journal-title":"J Clin Diagn Res"},{"key":"4287_CR38","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.4103\/0976-9668.166051","volume":"6","author":"AK Hazarika","year":"2015","unstructured":"Hazarika AK, Singh PK (2015) Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Nat Sci Biol Med 6:S10\u2013S12. \n                    https:\/\/doi.org\/10.4103\/0976-9668.166051","journal-title":"J Nat Sci Biol Med"},{"key":"4287_CR39","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/eye.2011.75","volume":"25","author":"A Kheirkhah","year":"2011","unstructured":"Kheirkhah A, Zavareh MK, Farzbod F, Mahbod M, Behrouz MJ (2011) Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond) 25:872\u2013880. \n                    https:\/\/doi.org\/10.1038\/eye.2011.75","journal-title":"Eye (Lond)"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-019-04287-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T00:08:03Z","timestamp":1583626083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-019-04287-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4287"],"URL":"https:\/\/doi.org\/10.1007\/s00417-019-04287-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,9]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not present any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}